investigators news from FierceBiotech

Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too Read more...

The brouhaha over heparin has cast a spotlight on the use of animal products in therapies. It also Read more...

More bad news on the big drought of new drug approvals. Not only are approvals at a 25-year low while non-approvable letters and black box warnings are on the rise. Now the RPM Report says that Read more...

Denmark's Novo Nordisk has seen its shares surge on the news that Liraglutide has produced positive results in two late-stage trials, positioning it for regulatory approval next year. The two Phase Read more...

A UK lab jointly owned by Merck and Sanofi-Aventis insists that there is no evidence that it played any role in a recent outbreak of foot-and-mouth disease, Read more...

Press Release: Scientists Discover Key to Manipulating Fat

Read more...

It's far too early to tell just how damaging the new report about GlaxoSmithKline (below) will be to the industry. The BBC is reporting that the company distorted data in an attempt to gain …

Read more...

Press Release: The Medicines Company's Cleviprex Phase III Safety Trials Meet Pre-Specified Objectives

Read more...

India has given Peregrine Pharmaceuticals a green light to conduct clinical trials of its experimental therapy Cotara for a type of brain cancer. "We believe this new clinical trial will be a cornerstone of our future plans to develop Cotara for the treatment of this deadly form of cancer," said Steven W. King, president and CEO of Peregrine. "We are moving this program forward in India because of the high level of experience of the participating neurosurgeons with CED delivery, the …

Read more...

OrthoLogic has abandoned a multi-dose Phase IIb study of its experimental fracture repair drug Chrysalin after it failed to produce better results than a placebo. Investigators had been testing five different doses of Chrysalin, but determined that patients were not able to remove their casts any quicker after taking the drug. OrthoLogic researchers will now focus on advancing TP508 for fracture repair.

"We interrupted enrollment in the Phase IIb clinical trial in mid-March 2006 in …

Read more...